Screener
Opus Genetics IRD Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034084
| Line item | For the Three Months Ended March 31, 2026 | For the Three Months Ended March 31, 2025 |
|---|---|---|
| License and collaborations revenue | $2,157 | $4,370 |
| Operating expenses: | ||
| Research and development | 10,577 | 7,953 |
| General and administrative | 5,944 | 6,346 |
| Total operating expenses | 16,521 | 14,299 |
| Loss from operations | (14,364) | (9,929) |
| Fair value change in warrant liabilities | (51,364) | 2,805 |
| Financing costs | (582) | (1,372) |
Item 1. Financial Statements
FAQ
- What is Opus Genetics's total revenue?
- Opus Genetics (IRD) reported total revenue of $2.16M in Q1 2026.
- How has Opus Genetics's total revenue changed year-over-year?
- Opus Genetics's total revenue decreased by 50.6% year-over-year, from $4.37M to $2.16M.
- What is the long-term trend for Opus Genetics's total revenue?
- Over 3 years (2022 to 2025), Opus Genetics's total revenue has grown at a -29.1% compound annual growth rate (CAGR), from $39.85M to $14.2M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Opus Genetics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude